Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679780 · ClinicalTrials.gov registry record · Phase 1
The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction
A Phase 1 study, sponsored by The University of Texas at Arlington.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03679780: Completed Phase 1 study, sponsored by The University of Texas at Arlington.
NCT03679780 is a Phase 1 study that has completed, run by The University of Texas at Arlington. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03679780, a Phase 1 study, has completed, sponsored by The University of Texas at Arlington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of the study is to examine the possible mechanisms of impaired cutaneous microvascular function through local heating along with administration of vasoconstrictors.
Primary Outcome
Determine to what extent overactivation of Endothelin Receptor Type A/B or L-Arginine deficiencies have on vasodilatory capacity by delivering specific Endothelin receptor agonists or supplemental L-Arginine via intradermal microdialysis. Vasodilation will be elicited by local heating and changes in skin blood flux will be assessed via laser Doppler fluxmetry. All changes in skin blood flux will be normalized and reported as a percentage of maximal flux.
Interventions
- DRUG Sodium Nitroprusside
- DRUG L-Arginine
- DRUG BQ-123
- DRUG BQ-788
- DRUG NG Nitro L Arginine Methyl Ester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 1 |
What the finished NCT03679780 record still lists
NCT03679780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Sodium Nitroprusside is the first listed.
NCT03679780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03679780 about?
NCT03679780 is a clinical study titled "The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction". The goal of the study is to examine the possible mechanisms of impaired cutaneous microvascular function through local heating along with administration of vasoconstrictors.
What is the current status of trial NCT03679780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-10-01. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT03679780?
The interventions under investigation include: Sodium Nitroprusside (DRUG), L-Arginine (DRUG), BQ-123 (DRUG), BQ-788 (DRUG), NG Nitro L Arginine Methyl Ester (DRUG).
Who is sponsoring clinical trial NCT03679780?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03679780's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI